ACADIA Pharmaceuticals In... (ACAD)
ACADIA Pharmaceuticals Statistics
Share Statistics
ACADIA Pharmaceuticals has 166.79M shares outstanding. The number of shares has increased by 0.95% in one year.
Shares Outstanding | 166.79M |
Shares Change (YoY) | 0.95% |
Shares Change (QoQ) | 0.24% |
Owned by Institutions (%) | 98.05% |
Shares Floating | 165.49M |
Failed to Deliver (FTD) Shares | 249 |
FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 17.12M, so 10.29% of the outstanding shares have been sold short.
Short Interest | 17.12M |
Short % of Shares Out | 10.29% |
Short % of Float | 10.42% |
Short Ratio (days to cover) | 4.09 |
Valuation Ratios
The PE ratio is 13.43 and the forward PE ratio is 23.45. ACADIA Pharmaceuticals's PEG ratio is -0.03.
PE Ratio | 13.43 |
Forward PE | 23.45 |
PS Ratio | 3.17 |
Forward PS | 1.8 |
PB Ratio | 4.15 |
P/FCF Ratio | 19.34 |
PEG Ratio | -0.03 |
Enterprise Valuation
ACADIA Pharmaceuticals has an Enterprise Value (EV) of 2.77B.
EV / Sales | 2.9 |
EV / EBITDA | 27.69 |
EV / EBIT | 17.58 |
EV / FCF | 17.64 |
Financial Position
The company has a current ratio of 2.38, with a Debt / Equity ratio of 0.07.
Current Ratio | 2.38 |
Quick Ratio | 2.32 |
Debt / Equity | 0.07 |
Debt / EBITDA | 0.52 |
Debt / FCF | 0.33 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is 30.9% and Return on Invested Capital is 25.22%.
Return on Equity | 30.9% |
Return on Assets | 19.07% |
Return on Invested Capital | 25.22% |
Revenue Per Employee | $1.47M |
Profits Per Employee | $346.79K |
Employee Count | 653 |
Asset Turnover | 0.81 |
Inventory Turnover | 3.73 |
Taxes
Income Tax | 31.62M |
Effective Tax Rate | 12.25% |
Stock Price Statistics
The stock price has increased by -9.72% in the last 52 weeks. The beta is 0.43, so ACADIA Pharmaceuticals's price volatility has been higher than the market average.
Beta | 0.43 |
52-Week Price Change | -9.72% |
50-Day Moving Average | 18.22 |
200-Day Moving Average | 16.89 |
Relative Strength Index (RSI) | 39.19 |
Average Volume (20 Days) | 1.89M |
Income Statement
In the last 12 months, ACADIA Pharmaceuticals had revenue of 957.8M and earned 226.45M in profits. Earnings per share was 1.37.
Revenue | 957.8M |
Gross Profit | 875.96M |
Operating Income | 230.79M |
Net Income | 226.45M |
EBITDA | 100.16M |
EBIT | 84.28M |
Earnings Per Share (EPS) | 1.37 |
Balance Sheet
The company has 319.59M in cash and 51.99M in debt, giving a net cash position of 267.59M.
Cash & Cash Equivalents | 319.59M |
Total Debt | 51.99M |
Net Cash | 267.59M |
Retained Earnings | -2.2B |
Total Assets | 1.19B |
Working Capital | 543.45M |
Cash Flow
In the last 12 months, operating cash flow was 157.72M and capital expenditures -523K, giving a free cash flow of 157.2M.
Operating Cash Flow | 157.72M |
Capital Expenditures | -523K |
Free Cash Flow | 157.2M |
FCF Per Share | 0.95 |
Margins
Gross margin is 91.46%, with operating and profit margins of 24.1% and 23.64%.
Gross Margin | 91.46% |
Operating Margin | 24.1% |
Pretax Margin | 26.94% |
Profit Margin | 23.64% |
EBITDA Margin | 10.46% |
EBIT Margin | 24.1% |
FCF Margin | 16.41% |
Dividends & Yields
ACAD does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | 7.45% |
FCF Yield | 5.17% |
Analyst Forecast
The average price target for ACAD is $23, which is 38.3% higher than the current price. The consensus rating is "Buy".
Price Target | $23 |
Price Target Difference | 38.3% |
Analyst Consensus | Buy |
Analyst Count | 16 |
Scores
Altman Z-Score | 2.64 |
Piotroski F-Score | 3 |